Literature DB >> 28370067

Resolution of acyclovir-associated neurotoxicity with the aid of improved clearance estimates using a Bayesian approach: A case report and review of the literature.

W A Watson1, N J Rhodes1,2, I A Echenique3, M P Angarone4, M H Scheetz1,2.   

Abstract

WHAT IS KNOWN AND
OBJECTIVE: Neurotoxicity is a side effect of acyclovir. We report the first case, to our knowledge, whereby Bayesian-informed clearance estimates supported a therapeutic intervention for acyclovir-associated neurotoxicity. CASE
SUMMARY: A 62-year-old male with the diagnosis of disseminated zoster was being treated with intravenous (IV) acyclovir when he developed symptoms of acute neurotoxicity. Acyclovir had been dose-adjusted for renal dysfunction according to traditional creatinine clearance estimates; however, as the patient was also on vancomycin, Bayesian estimates of vancomycin clearances were performed, which revealed a 2-fold lower creatinine clearance. In response to the Bayesian estimates, acyclovir was discontinued, and improvements in mentation were noted within 24 hours. WHAT IS NEW AND
CONCLUSION: Alternate approaches to estimate renal function beyond Cockcroft-Gault, such as a Bayesian approach used in our patient, should be considered when population estimates are likely to be inaccurate and potentially dangerous to the patient.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  acyclovir; adverse effects; pharmacodynamics; pharmacokinetics; statistical model

Mesh:

Substances:

Year:  2017        PMID: 28370067      PMCID: PMC5404941          DOI: 10.1111/jcpt.12520

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  20 in total

1.  Aciclovir and valaciclovir neurotoxicity in patients with renal failure.

Authors:  Michael K Almond
Journal:  Nephrol Dial Transplant       Date:  2003-12       Impact factor: 5.992

2.  Low-dose acyclovir and acute renal failure.

Authors:  A Giustina; G Romanelli; A Cimino; G Brunori
Journal:  Ann Intern Med       Date:  1988-02       Impact factor: 25.391

Review 3.  Acyclovir neurotoxicity: clinical experience and review of the literature.

Authors:  J C Adair; M Gold; R E Bond
Journal:  South Med J       Date:  1994-12       Impact factor: 0.954

4.  The aciclovir metabolite CMMG is detectable in the CSF of subjects with neuropsychiatric symptoms during aciclovir and valaciclovir treatment.

Authors:  Anders Helldén; Jan Lycke; Tatiana Vander; Jan-Olof Svensson; Ingegerd Odar-Cederlöf; Lars Ståhle
Journal:  J Antimicrob Chemother       Date:  2006-03-15       Impact factor: 5.790

5.  High serum concentrations of the acyclovir main metabolite 9-carboxymethoxymethylguanine in renal failure patients with acyclovir-related neuropsychiatric side effects: an observational study.

Authors:  Anders Helldén; Ingegerd Odar-Cederlöf; Per Diener; Lisbeth Barkholt; Charlotte Medin; Jan-Olof Svensson; Juliette Säwe; Lars Ståhle
Journal:  Nephrol Dial Transplant       Date:  2003-06       Impact factor: 5.992

6.  Pharmacokinetics and tolerance of acyclovir, a new anti-herpesvirus agent, in humans.

Authors:  O L Laskin; J A Longstreth; R Saral; P de Miranda; R Keeney; P S Lietman
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

7.  Acyclovir-associated encephalopathy, lack of relationship between acyclovir levels and symptoms.

Authors:  R J de Knegt; H van der Pijl; L A van Es
Journal:  Nephrol Dial Transplant       Date:  1995       Impact factor: 5.992

8.  Acyclovir-induced neuropsychosis successfully recovered after immediate hemodialysis in an end-stage renal disease patient.

Authors:  Hung-Hsu Yang; Yu-Ping Hsiao; Hung-Chun Shih; Jen-Hung Yang
Journal:  Int J Dermatol       Date:  2007-08       Impact factor: 2.736

9.  Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation.

Authors:  J C Wade; J D Meyers
Journal:  Ann Intern Med       Date:  1983-06       Impact factor: 25.391

10.  Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function.

Authors:  James P Smith; Stephen Weller; Benjamin Johnson; Janet Nicotera; James M Luther; David W Haas
Journal:  Antimicrob Agents Chemother       Date:  2009-12-28       Impact factor: 5.191

View more
  5 in total

1.  Neurological and Psychiatric Adverse Effects of Antimicrobials.

Authors:  Madison K Bangert; Rodrigo Hasbun
Journal:  CNS Drugs       Date:  2019-08       Impact factor: 5.749

2.  Too Much of a Good Thing: Defining Antimicrobial Therapeutic Targets to Minimize Toxicity.

Authors:  Kevin J Downes; Jennifer L Goldman
Journal:  Clin Pharmacol Ther       Date:  2021-02-27       Impact factor: 6.875

3.  In silico trials: Verification, validation and uncertainty quantification of predictive models used in the regulatory evaluation of biomedical products.

Authors:  Marco Viceconti; Francesco Pappalardo; Blanca Rodriguez; Marc Horner; Jeff Bischoff; Flora Musuamba Tshinanu
Journal:  Methods       Date:  2020-01-25       Impact factor: 3.608

Review 4.  Acute kidney injury and acyclovir-associated encephalopathy after administration of valacyclovir in an elderly person with normal renal function: A case report and literature review.

Authors:  Tsuneaki Kenzaka; Kazuma Sugimoto; Ken Goda; Hozuka Akita
Journal:  Medicine (Baltimore)       Date:  2021-05-28       Impact factor: 1.817

5.  Cepharanthine Suppresses Herpes Simplex Virus Type 1 Replication Through the Downregulation of the PI3K/Akt and p38 MAPK Signaling Pathways.

Authors:  Yao Liu; Li Chen; Wenjun Liu; Dan Li; Jiuseng Zeng; Qiong Tang; Yuexin Zhang; Fei Luan; Nan Zeng
Journal:  Front Microbiol       Date:  2021-12-09       Impact factor: 5.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.